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The effects of combined and simultaneously applied localised 431C hyperthermia (HT) and an antivascular bacteriochlorophyll-
serine-based photodynamic therapy (Bchl-ser-PDT) on tumour growth and several microenvironmental parameters were examined.
Rats bearing DS-sarcomas were allocated to treatment groups: (i) sham-treatment (control), (ii) Bchl-ser-PDT (20mgkg
 1 i.v.), (iii)
localised HT, (iv) Bchl-ser-PDTþHT. The light source used was an infrared-A irradiator, which, by use of appropriate filters,
delivered the different ranges of wavelengths required. Following treatment, tumour volume was monitored. The greatest tumour
growth inhibition was seen with Bchl-ser-PDTþHT, and subsequent experiments identified the pathophysiological basis for this
effect. Red blood cell flux in tumour microvessels declined rapidly upon Bchl-ser-PDTþHT, reaching approximately 10% of initial
values by the end of treatment. Similarly, tumour oxygenation worsened, reaching almost anoxic levels by the end of the treatment
period. Assessment of metabolic parameters showed a pronounced increase in lactate levels and a decrease in ATP concentrations
after combined treatment. The results presented suggest that vascular collapse and flow stasis resulting in a deterioration of tumour
oxygenation and a switch from oxidative to glycolytic glucose turnover are key elements in the tumour eradication seen with this
novel approach in which an antivascular PDT and HT are combined and simultaneously applied.
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Photodynamic therapy (PDT) is increasingly becoming accepted as
a treatment option for a variety of oncological, dermatological,
ophthalmic and cardiovascular diseases (Dougherty, 2002). In
oncological applications, treatment is usually based on the
photosensitisation of tumour cells with subsequent light exposure
leading to death of the malignant cells. The most commonly used
photosensitisers have been the haematoporphyrin derivatives,
which do however have a number of drawbacks including an often
poor selectivity in terms of tumour drug accumulation and low
extinction coefficients so that relatively large amounts of drug and/
or light are needed in order to obtain a satisfactory photother-
apeutic response. Additionally, light of wavelengths corresponding
to the absorption maximum at approximately 630nm only
penetrates poorly into tissues, thus presenting a limitation
concerning the depth of treatment (usually less than 4–5mm).
Due to a high drug accumulation in normal skin, patients may also
be confronted with skin phototoxicity which may persist for up to
8 weeks after treatment. These issues have led to the development
of a further generation of photosensitisers, a number of which are
already being investigated for clinical application. One potentially
interesting group of substances are the chlorophyll derivatives. Of
these, bacteriochlorophyll-serine (Bchl-ser) – the photosensitizer
used in the present study – shows a number of features that
underline the potential of soluble bacteriochlorophyll derivatives
in tumour photodynamic therapy. These features include photo-
toxicity, which under in vitro conditions is approximately 200
times greater than the haematoporphyrin derivatives, strong
absorption at 760–80nm (allowing deeper light penetration into
tissues), rapid tissue clearance and minimal extravasation from the
circulation (Rosenbach-Belkin et al, 1996).
Traditionally in PDT – as with chemo- and radiotherapy - the
primary treatment target was the tumour cell. Although vascular
injury was considered to be important in the process of tumor
eradication, it was feared that partial vascular shutdown, as
observed with some photosensitisers, may limit treatment efficacy
due to a reduction in blood flow and a subsequent decrease in O2
delivery (Henderson and Fingar, 1989). More recently, however,
attention has been given to the possibility of treating solid tumours
by PDT targeted at the tumour vasculature (Fingar, 1996, 1999;
Chen et al, 2002). Certainly, when PDT is applied for age-related
macular degeneration, the blood vessels are the sole treatment
target (Dougherty, 2002). In animal experiments, Bchl-ser was
found to produce maximum antitumour effects when illumination
was applied close to the time of drug injection when the
photosensitiser concentration in blood was at its highest
(Zilberstein et al, 2001), with microscopic examination primarily
revealing extensive vascular damage. Bchl-ser thus, besides
exhibiting a number of favourable photosensitiser properties,
appears to be a suitable candidate for use in PDT targeted at the
tumour vasculature.
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sThe aim of the present study was to attempt a novel
combination of an antivascular PDT treatment and localised
hyperthermia (HT) for enhanced antitumour therapy. Clinically,
HT alone is not an appropriate option for the curative treatment of
human tumours. However, a number of clinical studies have
indicated a clear benefit when HT was combined with other
therapy modalities, in particular radiotherapy (Overgaard et al,
1996; Vernon et al, 1996; Prosnitz et al, 1999; van der Zee et al,
2000). As far as a combination of HT with PDT is concerned, a
number of in vitro and in vivo studies suggest that the antitumour
effect of PDT may be enhanced by HT (Christensen et al, 1984;
Henderson et al, 1985; Mang and Dougherty, 1985; Levendag et al,
1988; Chen et al, 1996; Rasch et al, 1996; Kelleher et al, 1999;
Orenstein et al, 1999). Considering the results obtained in such
studies, a simultaneous delivery of light and heat, though
technically more challenging, may be preferable in terms of a
maximum cytotoxic effect, and certainly, from a clinical point of
view, a therapy combination which can be applied in a single
session would be favourable. A method for the application of PDT
and controlled localised hyperthermia in a single session has
previously been described by our group (Kelleher et al, 1999),
and the present paper attempts to examine the antitumour benefit
which might be achieved by applying the combination of a
vascular-targeted PDT treatment simultaneously with HT.
At the same time, the consequences of such a therapy for
the tumour microenvironment, in terms of perfusion, oxygenation
and metabolic parameters, have been examined for the first time
using an experimental tumour model in the rat, since modifica-
tions of these parameters can crucially impact on the therapeutic
outcome.
MATERIALS AND METHODS
Animals and tumours
Solid tumours grew subcutaneously following injection of DS-
sarcoma cells (0.4ml approx. 10
4cellsml
 1) into the hind foot
dorsum of male Sprague–Dawley rats (Charles River Wiga,
Sulzfeld, Germany; receiving a standard diet and water ad libitum;
body weight at time of tumour implantation: 180–210g). Approx.
1 week after implantation, when a tumour volume of 0.7–1.0ml
had been reached, animals were anaesthetised with sodium
pentobarbital (40mgkg
 1 i.p., Narcoren
s, Merial, Hallbergmoos,
Germany). Throughout all experiments, animals lay supine on a
thermostatically controlled heating pad and the rectal temperature
maintained at 37.5–38.51C. Animals breathed room air sponta-
neously. In the case of the acute experiments (laser Doppler flux,
oxygenation status, metabolite concentrations), polyethylene
catheters were placed into the thoracic aorta via the left common
carotid artery and into the right external jugular vein (to allow
administration of additional anaesthetic, as necessary). Contin-
uous monitoring of the mean arterial blood pressure (MABP) was
possible via attachment of the arterial catheter to a pressure
transducer (P23 ID, Gould, Oxnard, CA, USA). After the surgical
procedures, animals were allowed to stabilise and treatment
commenced once constant baseline readings for laser Doppler
flux or oxygenation were obtained for at least 20min.
Photosensitiser
The photosensitiser used in this study was Bchl-ser. This water-
soluble derivative of the natural pigment bacteriochlorophyll-a,
was prepared as described previously (Scherz et al, 1994). The
absorption spectrum for Bchl-ser is shown in Figure 1. Subsequent
to preparation, the photosensitizer was stored under argon at
 201C. The Bchl-ser was dissolved in 95% ethanol (5mg/100ml)
and then diluted in 1ml phosphate-buffered saline immediately
prior to administration via a tail vein so that animals received a
dose of 20mgkg
 1 body weight. In the case of combined Bchl-ser-
PDTþHT, the photosensitizer was injected 10min following
commencement of HT. Correspondingly, Bchl-ser-PDT involved
photosensitizer injection 10min after commencement of illumina-
tion. Control animals received an equivalent volume of ethanol
(400mlkg
 1) in 1ml phosphate-buffered saline.
Treatments
Group I (control): sham treatment. Group II (Bchl-ser-PDT):
animals received Bchl-ser (20mgkg
 1 i.v.) and ‘non-thermal’
illumination (665–800nm; 125mW; 230Jcm
 2). Group III (HT):
localised HT at 431C (665–1400nm; 760mWcm
 2; 1596Jcm
 2).
Group IV (Bchl-ser-PDTþHT): animals treated with Bchl-ser
(20mgkg
 1 i.v.) and localised tumour HT for 60min at 431C
(665–1400nm; 760mWcm
 2; 1596cm
 2; for this group, the light
dose in terms of the effective spectral range of the photosensitising
drug used in this study–from 665 to 800nm was identical to that
of group II, i.e., 230Jcm
 2).
The radiation delivery system used has been described in detail
previously (Vaupel et al, 1992; Kelleher et al, 1995, 1999). The
energy source is a halogen lamp emitting over the spectral range
420–1400nm. As described above, experimental groups were
treated with different wavelength windows. For group II (Bchl-ser-
PDT), a long-wave pass (665nm) and a short-wave-pass filter
(800nm) were inserted into the radiation path to obtain
wavelengths 665–800nm, so that the infrared bands which would
otherwise result in heating were removed. Only the long-wave-pass
filter was inserted in the case of groups III and IV (665–1400nm)
so that HT could be applied. The radiation system additionally
encompasses a water filter responsible for two strong, distinct
absorption bands at 944 and 1180nm, which would otherwise be
absorbed by the most superficial skin layers resulting in painful
sensations and exsiccosis. The heating patterns achieved with this
system, showing therapeutically relevant temperatures in tissues
up to a depth of 1.2cm, have been described (Vaupel et al, 1992;
Kelleher et al, 1995), as have the resulting tumour temperature
distributions (Kelleher et al, 1995). In groups where HT was
applied (III and IV), a feedback control system involving the
measurement of temperature in the tumour centre with a
thermocouple (+ 250mm; type 2ABAc, Philips, Kassel, Germany)
was used to heat tumours (0.41Cmin
 1) to a set temperature of
431C. Following the 20 min heat-up phase, the tumour temperature
was maintained at 431C for 60min by regulation of the source
which was switched on and off intermittently by the feedback
control system, resulting in an average total energy dose of
1596Jcm
 2 over the complete 80 min treatment period, as
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Figure 1 Absorption spectrum for a solution of bacteriochlorophyll-
serine in acetone.
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smeasured in pilot studies. These pilot studies were also used to
obtain information concerning the pattern of irradiation and
showed that, on average, the tumours used were irradiated for 1.3s
followed by a non-illumination period of 2s over the 80min
treatment period. This pattern was subsequently used for the Bchl-
ser-PDT treatment (Group II) so that the light delivered in the
range from 665–800nm was equal for all groups in which tumours
were illuminated. The fluence rate for this wavelength range was
125mWcm
 2 and the total energy dose was 263Jcm
 2. However,
since the photosensitizer was administered 10min after com-
mencement of illumination (in order to correspond to the Bchl-
ser-PDTþHT group), the ‘effective’ total energy dose (i.e., light
involved in a photodynamic effect) was 230Jcm
 2. A radiometer/
photometer (IL1400A, International Light, Newburyport, MA,
USA) with a calibration traceable to the National Physical
Laboratory (USA) was used for light dosimetry purposes. The
irradiation was applied solely to the tumour, the remainder of the
animal being shielded by aluminium foil.
It should be noted that the light doses administered in the Bchl-
ser-PDT group were not selected on the basis of conventionally
used light doses in PDT, but rather arose from the properties of the
light source used and the energy doses necessary to induce 431C
HT in those groups where tissue heating was induced.
Assessment of in vivo tumour response
The three orthogonal diameters (d) of the tumours were measured
on a daily basis so that tumour volume (V) could be determined
using the ellipsoid approximation V¼p/6 d1 d2 d3. The end
point of the tumour response study was a tumour volume of 3.5ml,
rather than survival. This target value was selected to ensure that
the tumour burden at the end of the study never exceeded 1% of
body weight. Animals whose tumours did not reach the target
volume were monitored for 90 days.
Laser Doppler flowmetry
Determination of the red blood cell (RBC) flux in tumour
microvessels was performed using a laser Doppler flowmeter
(Periflux 2B, Perimed, Stockholm, Sweden). This method relies on
the Doppler shift, assessing the frequency change undergone by
light when reflected by moving objects, such as RBCs, and is a
valid technique for measurement of microcirculatory function in
small tissue areas (Smits et al, 1986). RBC flux signals were
obtained from a central location within the tumour using a needle
probe (PF 302, o.d.: 0.45mm). Using a 24-gauge needle, a small
incision of the skin covering the tumour was made to allow
insertion of the laser Doppler probe. Recording of the total
backscattered light during the monitoring period ensured an
optimum and constant probe positioning and minimum tissue
compression. At the end of each experiment, the laser Doppler
probe was left in place and the animal given an overdose of
anaesthetic so that the biological zero RBC flux signal could be
established and subtracted from all previous values for each
animal. Data were subsequently expressed relative to the RBC flux
obtained immediately prior to commencement of treatment.
Tumour oxygen tension measurements
Polarographic assessment of tumour oxygenation was carried out
using a flexible O2-sensitive catheter electrode (+ 350mm, LICOX
pO2, GMS, Kiel, Germany), which was inserted into the tumour for
continuous monitoring. Calibration of the pO2 electrode was
carried out using room air in a constant temperature chamber,
taking into account the prevalent barometric pressure. Data were
subsequently expressed relative to the value obtained immediately
prior to commencement of treatment.
Determination of metabolite concentrations
In a further series of experiments, the tumour-bearing foot
of the anaesthetised animals was rapidly frozen in liquid N2
immediately after completion of treatment. Two-thirds of the
tumour mass was then ground to a fine powder and freeze-dried.
Glucose and lactate concentrations were then determined using
standard enzymatic assay kits (Boehringer-Mannheim, Mannheim,
Germany), and global ATP, ADP and AMP concentrations were
measured with reversed-phase HPLC, as described previously
(Kru ¨ger et al, 1991).
Cryosections (20mm) were prepared from the remainder
of the tumour. These were heat-inactivated at 801C for 5min
before storage at  801C. Microregional distributions of lactate
and ATP concentrations were subsequently assessed using
single-photon imaging and bioluminescence techniques (for more
details see Mueller-Klieser and Walenta, 1993). For this, a frozen
tumour section mounted onto the underside of a glass micro-
scope slide was placed onto another slide containing a well
into which an aliquot of a cooled mixture of enzymes and
coenzymes had been pipetted. Specific to the substrate undergoing
investigation, these enzymes provide a link to a luciferase reaction.
The whole preparation was warmed to 201C and the spatial
distribution of the bioluminescence intensity within the tissue
section directly measured using a microscope (Axiophot, Zeiss,
Go ¨ttingen, Germany) and an imaging photon-counting system
(Argus 100, Hamamatsu, Herrsching, Germany). Using this
method, a spatial resolution of approximately 50mm could be
achieved. Heat-inactivated tissue homogenates with defined
concentrations of lactate and ATP were treated in the same way
as tumour sections and used to calibrate the bioluminescence
intensity.
Experimental guidelines and statistical methods
All experiments were carried out in strict accordance with the
UKCCCR guidelines (Workman et al, 1998) and the German Law
for Animal Protection of 1987. All procedures had also been
reviewed by the responsible regional Ethics Committee. Kaplan–
Meier statistics were applied to describe in vivo tumour growth
characteristics and a log-rank analysis used to assess the
significance of differences between the various treatment groups.
All other analyses were carried out using the Wilcoxon test for
unpaired samples. The significance level in all cases was set at
a¼5%.
RESULTS
All animals recovered rapidly following treatment, with no
phototoxic effects on normal skin being recorded. Assessment of
tumour volume for up to 90 days provided the basis for a Kaplan–
Meier analysis, showing the probability of the tumour volume
being less than 3.5ml during the observation period (Figure 2).
Spontaneous cure was not seen in any of the sham-treated animals
(control), with the target volume being reached approximately 7
days after treatment. Tumour treatment with localised 431CH T
resulted in a significant increase in the probability of tumours not
reaching the target volume (16% on day 90) compared to the
control group (Po0.001). Bchl-ser-PDT alone also effectively
inhibited tumour growth with a probability of 36% on day 90
(Po0.001). The greatest inhibition of tumour growth was seen
upon Bchl-ser-PDTþHT, with a probability of tumours not
reaching the target volume of 78%, 90 days after treatment
(Po0.001). Of the tumours which did not reach the target volume
within the observation period, the majority showed no evidence of
tumour presence on macroscopic examination. Only one tumour
treated with Bchl-ser-PDTþHT showed slow tumour recurrence
from day 30 after treatment onwards, which still had not reached
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sthe target volume by day 90. The differences between the Bchl-ser-
PDTþHT and Bchl-ser-PDT groups, while not being significant
upon log-rank analysis, do suggest a trend towards a greater
antitumour effect with the combined therapy form (P¼0.083).
Considering this, the subsequent experiments were carried out to
elucidate the impact of the combined therapy on tumour
perfusion, oxygenation and metabolic microenvironment, in
comparison to the effects of HT alone, since such effects may
play a key role in the observed inhibition of tumour growth.
Changes in MABP, red blood cell flux (RBC flux) in tumour
microvessels and tumour oxygenation over the whole observation
period are shown in Figure 3. Upon commencement of treatment
with HT alone, a steady increase (up to 80% above initial values) in
RBC flux was seen, with this elevation remaining until the end of
the treatment period. Upon Bchl-ser-PDTþHT treatment, a
characteristic biphasic change in RBC flux was seen. Within the
first 15min of treatment, RBC flux decreased to 50%. This decrease
was followed by a transient, partial recovery, lasting approximately
10min. Thereafter, a further steady decline in RBC flux was
observed, reaching values approximately 10% of the initial flux.
This low flux level endured throughout the remainder of the
observation period (Figure 3, centre panel). Tumour oxygenation,
as measured polarographically, showed similar changes to those
seen for RBC flux. Upon HT treatment, an increase in pO2 was
seen, which reached an apex at a level 50% above initial values
approximately 30min after the commencement of treatment.
Thereafter, tumour pO2 remained elevated throughout the
observation period. With Bchl-ser-PDTþHT treatment, a biphasic
response was again seen, with an initial 30% decrease, followed by
a transient plateau phase. Thereafter, a further steady decrease was
seen reaching values approximating anoxic levels from 35min
onwards (Figure 3, lower panel). Since tumour red blood cell flux
and oxygenation changes may be due to alterations in perfusion
pressure, MABP was also monitored over the observation period
(Figure 3, upper panel). During HT treatment, MABP remained
constant. During Bchl-ser-PDTþHT treatment, a small increase in
MABP (E10mmHg) was seen, which was maintained for the
remainder of the observation period. This finding verifies that the
decrease in tumour RBC flux and oxygenation seen upon Bchl-ser-
PDTþHT treatment is not attributable to a decrease in perfusion
pressure.
Examples of colour-coded images of microregional ATP and
lactate distributions in tumour sections obtained using single-
photon imaging and bioluminescence techniques are shown in
Figure 4. Compared to images obtained in control tumours,
treatment with HT caused a depletion of ATP levels, an effect that
became even more pronounced upon Bchl-ser-PDTþHT treat-
ment, where hardly any tumour areas with ATP concentrations
41m M were seen. When the lactate distribution images were
compared, HT appeared to induce a slight increase in lactate levels.
Upon Bchl-ser-PDTþHT treatment, distinct and extensive in-
creases in lactate concentrations were observed, with numerous
regions showing concentrations 440mM.
The treatment-induced changes in lactate and ATP concentra-
tions seen using single-photon imaging and bioluminescence
techniques were confirmed using methods assessing global
metabolite concentrations (Table 1). Significant increases in lactate
concentrations were only seen upon Bchl-ser-PDTþHT (Po0.01),
where the concentration of lactate almost doubled upon treatment.
ATP levels were reduced upon treatment, with Bchl-ser-PDTþHT
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scausing the most pronounced reductions (Po0.05). Global glucose
levels were also assessed, although no significant changes were
evident.
DISCUSSION
This paper describes for the first time the antitumour effect of
combined Bchl-ser-PDTþHT, as compared to the action of Bchl-
ser-PDT or HT alone. Additionally, data are presented on the
influence of such a combined therapy on tumour perfusion,
oxygenation and metabolic microenvironment. The effectiveness
of such a combined approach is demonstrated by the high
probability (78%) of tumours not reaching the target volume. Of
the tumours observed up to day 90, the majority showed no
evidence of tumour presence, thus underlining the therapeutic
potential of PDT combined with HT.
A number of in vitro and in vivo studies have suggested a
possible role for HT in combination with conventional PDT
(Christensen et al, 1984; Mang and Dougherty, 1985; Chen et al,
1996; Rasch et al, 1996; Orenstein et al, 1999), although few of
these studies have addressed the logistical difficulties of applying
the two treatment components simultaneously, despite the fact that
this may be desirable for application in the clinical setting. In the
present study, an easily applicable technique was used to
simultaneously apply Bchl-ser-PDT and HT using a single,
nonlaser radiation source. The use of a nonlaser system is
favourable, since the high purchase and maintenance costs of
often complex laser systems are a major drawback to PDT
achieving widespread clinical acceptance (Stringer, 1995).
The combination of an antivascular PDT treatment with
localised HT, as applied in this study, is based on a number of
considerations. Firstly, Bchl-ser is injected i.v. 10min after
commencement of HT, at a time when the tumour is still in the
heating-up phase and has a temperature of approximately 401C. At
this point in time a mean increase in tumour RBF flux of E10%
was observed, which could therefore be exploited to enhance the
delivery of Bchl-ser to the tumour tissue. Secondly, the photo-
dynamic process is known to be inherently temperature dependent
(Gottfried and Kimel, 1991), and thus PDT in heated tissue should
show an increased cytotoxic effect. Clinically, one obstacle to an
effective hyperthermia treatment in human tumours is the inability
to obtain a therapeutically relevant temperature elevation in the
tumour tissue. This may be partly due to limitations of the heating
equipment used, but also due to the relatively high perfusion rates
that have been encountered in human tumours, leading to an
unwanted dissipation of heat away from the malignancy (Vaupel
and Kelleher, 1995). Thus, the combination of a vascular-based
PDT with HT may facilitate and homogenise tissue heating by
limiting the thermal wash-out. In other studies using vasoactive
flow-reducing agents, the effects of thermal damage induced by HT
were also shown to be augmented (for a review, see Prescott, 1995).
More recently, the use of the vascular targeting agent combreta-
statin A-4 in combination with hyperthermia has further demon-
strated the effectiveness of tumour heating in combination with a
vascular targeting agent (Eikesdal et al, 2001). Thirdly, a reduction
of tumour blood flow using vascular agents can cause an increase
in tumour acidity (Griffin et al, 2003), which in turn can potentiate
the effect of hyperthermia on tumour cells (Prescott, 1995). This
phenomenon may also be important during Bchl-ser-PDTþHT
treatment, since increased lactate concentrations were observed in
tumour tissue during this treatment. While the primary effect of
HT appears to be based on cellular and molecular mechanisms
leading to tumour cell death, effects of HT on the microcirculation
have been reported, with both increases and decreases in perfusion
being found depending on the thermal dose applied and on the
tumor model or – in the case of human tumours – on the
pathology of the tumour investigated, dramatic variations being
found between different regions of the same tumour (Kelleher et al,
1995). In the present study, HT alone resulted in a mean increase
in tumour perfusion, suggesting that the Bchl-ser-PDT component
is primarily responsible for the decrease in RBC flux, rapidly
nullifying the 10% increase induced by HT treatment immediately
prior to Bchl-ser administration. Of interest is also the biphasic
course of the changes in RBC flux and oxygenation seen during
Bchl-ser-PDTþHT. At present, the cause of this phenomenon is
not clear, but could involve drug relocalisation as has been
Figure 4 Examples of colour-coded distributions of ATP and lactate
concentrations measured in cryosections of DS-sarcomas following sham
treatment (control), localised hyperthermia (HT; 431C, 60min) or
combined Bchl-ser-based photodynamic therapy and HT (Bchl-ser-
PDTþHT) treatment.
Table 1 Global glucose, lactate and ATP concentrations in s.c.
DS-sarcomas following sham-treatment (control), localised 431C-HT or
combined Bchl-ser-based photodynamic therapy and HT (Bchl-ser-PDT+HT)
Treatment
group n
Glucose
concentration
(mM)
Lactate
concentration
(mM)
ATP
concentration
(mM)
Control 9 2.0370.29 12.6872.01 0.9970.24
HT 10 2.0270.30 11.7771.71 0.5670.10
Bchl-ser-PDT+HT 9 2.5170.39 22.8772.42 0.2770.11
(Po0.01) (Po0.05)
Values are presented as mean7s.e.m. n¼number of tumours evaluated. Significance
levels found upon testing differences between values obtained in control and treated
tumours are given.
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sreported for other photosensitisers (MacDonald and Dougherty,
2001). Certainly, further investigations are warranted if the
mechanisms underlying the exact antivascular effects of this
therapy are to be understood. Based on the findings presented in
this study, the therapeutic effectiveness of the Bchl-ser-PDTþHT
treatment is mediated by a rapidly induced vascular stasis, which
in turn can lead to the tumour cells being deprived of O2 and
nutrients. In earlier studies in which the effects of Bchl-ser-PDT
alone were monitored in tumour tissue, PDT-induced O2
consumption (Zilberstein et al, 1997) and changes indicative of
vascular stasis (Zilberstein et al, 2001) were also found. While
vascular damage has frequently been described as a consequence
of PDT, it is not a primary target when PDT is applied in the
clinical oncology setting, since, as with ionising radiation and
some chemotherapy agents, the PDT effect is O2-dependent
(Ho ¨ckel and Vaupel, 2001) and thus, O2 deprivation due to
vascular damage may reduce the treatment efficacy. In the case of
Bchl-ser, however, a phototoxic effect has also been seen under
hypoxic conditions (pO2 E2.5mmHg) (Chen et al, 1998) and a
model has been proposed in which the excitation of a Bchl-ser
molecule coordinated with an oxygen molecule prior to illumina-
tion leads to dehydrogenation of the Bchl moiety, with the
concomitant generation of hydroxyl radicals (Katz et al, 1998). In
the present study, the in vivo effectiveness of Bchl-ser-PDTþHT,
despite a rapid O2 depletion during treatment, would also suggest
that O2 deprivation is not a limiting factor in this setting. This is
further supported by a recent investigation of PDT-induced
damage using a related bacteriochlorophyll derivative, Pd-bacter-
iopheophorbide as the photosensitiser in human prostate xeno-
grafts in mice (Koudinova et al, 2003). Here, the extent of PDT-
induced damage was monitored by the immunohistochemical
tracking of lipid peroxidation (LP). Lipid peroxidation products
could be identified which were localised exclusively around blood
vessels in the first hour after PDT, and were attributed to light-
dependent ROS formation. The majority of the tumour however,
showed evidence of LP 24–48h after treatment in an apparently
light-independent process. This damage is presumably associated
with free radical-associated chain reactions initiated by PDT, which
can take place regardless of blood stasis and lead to secondary
tumour destruction due to a PDT-induced hypoxic state. Thus, this
novel combined treatment may be particularly suitable for the
treatment of hypoxic tumours or tumour regions, since both
components appear able to exert a cytotoxic effect, even under
conditions of O2 deficiency. This study has also demonstrated that
significant metabolic changes can be observed directly after the
combined therapy. The doubling of the lactate concentration and
the ATP depletion correspond well with the changes seen in blood
flow and oxygenation, and are suggestive of a switch within the
tumour to glycolytic glucose turnover. Since PDT (and more so
PDT in combination with HT) is a modality in which a number of
treatment parameters related to the photosensitiser and light (drug
dose, drug-light interval, light dose, etc) used need to be selected,
studies have also been carried out in which magnetic resonance
spectroscopy (MRS) techniques have been used to try to predict
PDT outcome at the time of treatment. In one such study (Bremner
et al, 1999), a clear relationship was seen between MRS
measurements of energy metabolism immediately following PDT
and the ultimate effect on the tumour in terms of regrowth delay.
The data obtained in the present study would also support the
concept that monitoring of ATP or lactate levels may provide
information on the effectiveness of PDT-based treatments.
In conclusion, an effective tumour therapy in which Bchl-ser-
PDT and HT have been combined and simultaneously applied has
been described, and the results presented suggest that vascular
collapse and flow stasis resulting in a deterioration of tumour
oxygenation and a switch from oxidative to glycolytic glucose
turnover are key elements in the tumour eradication seen with this
novel approach.
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